Since 1 July 2026, some people on Medicare can get one of three GLP-1 drugs for 50 dollars a month. The programme is called the Medicare GLP-1 Bridge, it runs until 31 December 2027, and a Vermont news site summed up its logic in a headline this week: for some patients, “the best path is to just get sicker”. We wanted to know whether the rule really says that. So we read it as the agency wrote it, in the Medicare fact sheet (product number 12234, June 2026) and in the prescriber FAQ of the Centers for Medicare & Medicaid Services, last updated 6 August 2026. This article is about how that rule is built. It is not about the drugs, and it says nothing about whether anyone should take them.
Three doors, and the price of each
The clinical criteria come in three tiers. A prescriber must attest that the patient is at least 18, is being prescribed the drug “to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity”, and meets one of the following:
- a body mass index of 35 or higher, with no further condition;
- a BMI of 30 or higher, together with heart failure with preserved ejection fraction, or uncontrolled hypertension (defined in the rule as a systolic pressure above 140 or a diastolic above 90 despite two antihypertensive medications), or chronic kidney disease stage 3a or above;
- a BMI of 27 or higher, together with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Read as a staircase, the rule is simple. The largest bodies walk in on size alone. Every step down in body size has to be paid for with a diagnosis. A person with a BMI of 33 and none of the listed conditions is outside. The same person with a heart attack behind them is inside. That is the sense in which the rule rewards getting sicker: not by intention, but by construction. Illness is the currency that buys down the size threshold.
None of this is unusual. It is the standard shape of a BMI access rule. NICE’s TA1152 in England uses a floor of 27 plus established cardiovascular disease. The EU marketing authorisation for Wegovy uses 30 alone or 27 with a “weight-related” problem. The Bridge simply stacks three of these floors on top of each other. The point of reading it is not that Medicare invented the staircase. It is that the staircase is now the international default, and nobody writes down what it teaches.
The door that closes when you get sick enough
Here is where the headline stops being accurate, and the rule becomes stranger than the headline.
If you have type 2 diabetes, moderate to severe obstructive sleep apnoea, or MASH (a form of fatty liver disease) with moderate to advanced scarring, you are not eligible for the Bridge. The FAQ is explicit: people with these diagnoses “are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria.” The reason is administrative. Those three indications are already coverable under the ordinary Part D drug benefit, so the Bridge sends you back to your drug plan. The fact sheet puts it gently: contact your plan, “they may already cover a GLP-1 drug for you.” May.
So the staircase has a trapdoor at the bottom. Getting sicker lowers your size threshold up to a point. Past that point, a further diagnosis moves you out of the 50-dollar programme altogether and into whatever your particular Part D plan decides, with its own deductible and its own prior authorisation. The rule does not reward getting sicker. It rewards getting sick in the right way and to the right degree.
The Vermont doctor quoted by VTDigger, Michelle Dorwart, president of the Vermont Academy of Family Physicians, described patients before July who were “kind of almost hoping that they’ll have diabetes”, because diabetes was the indication that got a GLP-1 paid for. That is her observation, reported by VTDigger on 3 September, not ours. The rule she is describing is the pre-Bridge Part D route, and it still exists, one trapdoor below the new one.
Frozen at the first injection
One more feature of the construction, and it is the one we found most telling. The criteria must be met “at the time of GLP-1 therapy initiation”, not at the time of the request. CMS gives the example itself: a patient who started in September 2024 with a BMI of 37 and now has a BMI of 34 qualifies, because the prescriber attests to the 37.
Turn that around. Two people stand in the same pharmacy with the same BMI of 34 and no listed condition. One of them started the drug two years ago and is inside the programme. The other never started and is outside. The rule does not measure the body in front of it. It measures the body’s history, and the larger that history, the better.
The prescriber attests to all of this “under penalty of perjury”, and CMS says it may check Medicare data to verify. There is no appeals process. A denied request can only be resubmitted.
Fifty dollars, “no matter your income level”
The fact sheet says the 50 dollars applies regardless of income. The FAQ explains what that means in practice: the Bridge runs outside the Part D benefit, so the payment does not count toward the deductible or the annual out-of-pocket limit, and “there is no low-income subsidy”. The subsidy that normally reduces drug costs for the poorest Medicare enrolees does not apply here. The flat fee is flat in both directions.
What the programme is for
The legal basis is worth a sentence, because it says what the exercise is. The Bridge runs under Section 402 of the Social Security Amendments of 1967, which lets the Secretary test whether “changes in methods of payment or reimbursement” would increase “the efficiency and economy of health services”. The FAQ adds that a planned larger model, called BALANCE, will not launch in 2027, and that the Bridge was extended to the end of 2027 partly so that CMS can “collect additional data on GLP-1 utilization to share with Part D plan sponsors”.
In plain words: it is a demonstration. The people who walk through the three doors are the sample, and the question being asked is about payment methods. That is a legitimate thing for an agency to study. It is also a reason to read the eligibility rule as what it is, a sampling frame drawn by body size and diagnosis, rather than as a statement about who deserves care.
Where VTDigger and the rule differ
We checked the newspaper’s numbers against the agency’s. The 50 dollars, the 1 July start and the end-of-2027 date all match. The BMI description does not quite: VTDigger writes that people “with lower BMIs” who have heart failure, hypertension or kidney disease are eligible, which leaves out that “lower” means 30 or above for that group and 27 or above for the prediabetes and heart-attack group, and that the heart-failure condition is specifically the preserved-ejection-fraction type. VTDigger also gives figures for how many Vermonters could qualify. We could not find a primary source for those numbers, so they are not in this article.
What we are not saying
Nothing here is a statement about whether these drugs work, for whom, or whether anyone should ask for them. That is not our subject and it is not our expertise. Our subject is the rule, and the rule says, in the agency’s own words, that a smaller body needs a diagnosis to be let in, a larger history counts more than a present measurement, and the sickest are sent somewhere else. We have written before about who gets in line when access is rationed by body size and about what happens when France pays and Germany does not. The Bridge is the same lesson with a US postmark.
Sources
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, Information for Providers (FAQ), page last modified 6 August 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers (read in full; clinical criteria, exclusions, initiation rule, attestation and appeals quoted from this page)
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, overview and FAQ, page last modified 13 July 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (copay, Section 402 authority, BALANCE, low-income subsidy)
- Medicare, “Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month”, fact sheet, CMS Product No. 12234, June 2026. https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf (read in full)
- CMS press release, “CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications”, 1 July 2026. https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
- Olivia Gieger, “For some patients seeking drugs like Ozempic, the best path is to just get sicker”, VTDigger, 3 September 2026. https://vtdigger.org/2026/09/03/for-some-patients-seeking-drugs-like-ozempic-the-best-path-is-to-just-get-sicker/ (source of the Dorwart quotation only)